CytoDyn Signs an Agreement with American Regent for Leronlimab to Treat COVID-19 Patients in the US

 CytoDyn Signs an Agreement with American Regent for Leronlimab to Treat COVID-19 Patients in the US

CytoDyn Collaborates with UK’s Department of Health to Provide Emergency Access to Leronlimab (PRO 140) for Patients with COVID-19

Shots:

  • CytoDyn to receive quarterly payments based on the profit-sharing arrangement and will supply Leronlimab to American Regent. American Regent will be responsible for the distribution of Leronlimab post completion of CytoDyn’s ongoing clinical trials including the FDA’s approval in the US
  • CytoDyn’s P-IIb/III trial is enrolling patients which will be evaluating leronlimab vs PBO (N=75) in 390 severe and critically ill COVID-19 patients in the ratio (2:1) and has already enrolled for P-II trial. The US FDA has also granted 60 eIND with expected clinical updates in the coming weeks
  • Leronlimab (PRO 140) IgG4 mAb that blocks CCR5 receptor and has received the US FDA’s Fast track Designation in combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. The product has also completed nine clinical trials in over 800 people and met 1Eps in P-III in HIV-infected treatment-experienced patients

Click here to read full press release/ article | Ref: CytoDyn | Image: Behance

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post